368 related articles for article (PubMed ID: 33236481)
1. Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States.
Reifsnider O; Kansal A; Pimple P; Aponte-Ribero V; Brand S; Shetty S
Diabetes Obes Metab; 2021 Mar; 23(3):791-799. PubMed ID: 33236481
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of second-line empagliflozin versus liraglutide for type 2 diabetes in the United States.
Reifsnider OS; Pimple P; Brand S; Bergrath Washington E; Shetty S; Desai NR
Diabetes Obes Metab; 2022 Apr; 24(4):652-661. PubMed ID: 34910356
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial.
Reifsnider OS; Kansal AR; Wanner C; Pfarr E; Koitka-Weber A; Brand SB; Stargardter M; Wang C; Kuti E; Ustyugova A
Am J Kidney Dis; 2022 Jun; 79(6):796-806. PubMed ID: 34752913
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.
Guzauskas GF; Rind DM; Fazioli K; Chapman RH; Pearson SD; Hansen RN
J Manag Care Spec Pharm; 2021 Apr; 27(4):455-468. PubMed ID: 33769850
[No Abstract] [Full Text] [Related]
5. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
Reifsnider OS; Kansal AR; Gandhi PK; Cragin L; Brand SB; Pfarr E; Fahrbach K; Ustyugova A
BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941549
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece.
Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsimihodimos V; Diogo V; Karpouzos G; Papageorgiou G; Kourlaba G
Clin Drug Investig; 2021 Apr; 41(4):371-380. PubMed ID: 33687695
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsapas A; Kourlaba G; Papageorgiou G; Maniadakis N
Clin Drug Investig; 2018 May; 38(5):417-426. PubMed ID: 29349708
[TBL] [Abstract][Full Text] [Related]
8. The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials.
Franch-Nadal J; Malkin SJP; Hunt B; Martín V; Gallego Estébanez M; Vidal J
Adv Ther; 2022 Jul; 39(7):3180-3198. PubMed ID: 35553372
[TBL] [Abstract][Full Text] [Related]
9. Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk.
Nguyen E; Coleman CI; Nair S; Weeda ER
J Diabetes Complications; 2018 Feb; 32(2):210-215. PubMed ID: 29157870
[TBL] [Abstract][Full Text] [Related]
10. First-line Treatment with Empagliflozin and Metformin Combination Versus Standard Care for Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease in Qatar. A Cost-Effectiveness Analysis.
Abushanab D; Al-Badriyeh D; Liew D; Ademi Z
Curr Probl Cardiol; 2022 Jun; 47(6):100852. PubMed ID: 33992426
[TBL] [Abstract][Full Text] [Related]
11. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S
Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease.
Ramos M; Foos V; Ustyugova A; Hau N; Gandhi P; Lamotte M
Diabetes Ther; 2019 Dec; 10(6):2153-2167. PubMed ID: 31602601
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting.
Eliasson B; Ericsson Å; Fridhammar A; Nilsson A; Persson S; Chubb B
Pharmacoecon Open; 2022 May; 6(3):343-354. PubMed ID: 35064550
[TBL] [Abstract][Full Text] [Related]
14. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.
Gorgojo-Martínez JJ; Malkin SJP; Martín V; Hallén N; Hunt B
J Med Econ; 2020 Feb; 23(2):193-203. PubMed ID: 31613199
[No Abstract] [Full Text] [Related]
15. Cost-effectiveness of intensification with sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes on metformin and sitagliptin vs direct intensification with insulin in the United Kingdom.
Pawaskar M; Bilir SP; Kowal S; Gonzalez C; Rajpathak S; Davies G
Diabetes Obes Metab; 2019 Apr; 21(4):1010-1017. PubMed ID: 30565386
[TBL] [Abstract][Full Text] [Related]
16. Short-term cost-effectiveness of oral semaglutide for the treatment of type 2 diabetes mellitus in the United States.
Cui J; Klepser DG; McAdam-Marx C
J Manag Care Spec Pharm; 2021 Jul; 27(7):840-845. PubMed ID: 34185562
[No Abstract] [Full Text] [Related]
17. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.
Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
Diabet Med; 2015 Jul; 32(7):890-8. PubMed ID: 25817050
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness Analysis of Empagliflozin in Japan Based on Results From the Asian subpopulation in the EMPA-REG OUTCOME Trial.
Kaku K; Haneda M; Sakamaki H; Yasui A; Murata T; Ustyugova A; Chin R; Hirase T; Shibahara T; Hayashi N; Kansal A; Kaspers S; Okamura T
Clin Ther; 2019 Oct; 41(10):2021-2040.e11. PubMed ID: 31561882
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial.
Kansal A; Reifsnider OS; Proskorovsky I; Zheng Y; Pfarr E; George JT; Kandaswamy P; Ruffolo A
Diabet Med; 2019 Nov; 36(11):1494-1502. PubMed ID: 31295358
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Empagliflozin and Metformin Combination Versus Standard Care as First-Line Therapy in Patients With Type 2 Diabetes Mellitus.
Abushanab D; Liew D; Marquina C; Al-Badriyeh D; Ademi Z
Endocr Pract; 2022 Jan; 28(1):16-24. PubMed ID: 34389513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
